Voices
OS Assessment in Cancer Drug Trials: A Luxury or a Necessity? – Common Sense Oncology
Sam Stevens, Laure-Anne Teuwen, Bishal Gyawali

OS Assessment in Cancer Drug Trials: A Luxury or a Necessity? – Common Sense Oncology

Common Sense Oncology shared a post on LinkedIn:

“Just published in The Lancet Oncology, a commentary by CSO members.

Drs. Sam Stevens, Laure-Anne Teuwen, and mentor Bishal Gyawali commends and provides further recommendations to the FDA’s latest guidance on randomized cancer drug trials.”

Title: Overall survival assessment in cancer drug trials: a luxury or a necessity?

Authors: Samuel X. Stevens, Laure-Anne Teuwen, Bishal Gyawali

Read the full article on The Lancet Oncology.

Cancer Drug Trials

More posts featuring Common Sense Oncology on OncoDaily.

Medically reviewed Oct 21, 2025 by Mariam Khachatryan, MD
Bishal Gyawali cancer FDA Laure-Anne Teuwen OncoDaily Oncology Samuel X Stevens The Lancet Oncology